STAB — Statera Biopharma Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.01m
- $5.97m
- $1.49m
Brief: Statera Biopharma Announces Proposed Underwritten Public Offering
Brief: Statera Biopharma Announces Revised Preliminary Revenue And Financial Results Of Fiscal Year 2021
Brief: Statera Biopharma Advances Next-Gen Proprietary Compositions Based On STAT-200 Platform
Brief: Statera Biopharma Submits Phase 1 Clinical Trial Protocol To FDA For Investigational Treatment Of Long-Haul Covid-19
Brief: Statera Biopharma Reports Central Institutional Review Board Approval of Trial for Pediatric Crohn's Disease
Statera Biopharma eyes worst day in nearly a year on $2 mln equity sale
Brief: Statera Biopharma Announces Pricing Of $2.0 Mln Registered Direct Offering
U.S. STOCKS ON THE MOVE-Calix, Codex DNA, Victoria's Secret
Statera rises on submission of late-stage trial protocol to FDA
Brief: Statera Biopharma Submits Phase 3 Clinical Trial Protocol to FDA for Investigational Treatment of Pediatric Crohn’s Disease
Brief: Statera Biopharma Announces First Patient Dosed In Study Of STAT-205 For Acute COVID
Statera rises as FDA lifts clinical hold on its radiation sickness therapy
Brief: Statera Biopharma Announces FDA Lifts Clinical Hold On Entolimod
Brief: Statera Biopharma Reports Q3 Loss Per Share $0.47
Brief: Statera Biopharma Inc Announces Institutional Review Board Approves Study Of STAT-205 For Acute Covid-19
U.S. STOCKS ON THE MOVE-Virgin Galactic, Goldman Sachs, U.S. hotel stocks
Brief: Cytocom Plans To Adopt New Corporate Name "Statera Biopharma, Inc."
Brief: Cytocom Inc Reports Q2 Loss Per Share Of $0.04 Excluding Minority Interests
Brief: Cytocom Q2 Loss Per Share Of $0.04